PSP Research LLC — 13F Holdings & Portfolio
CIK 2106939 · latest 13F-HR filed 2026-04-17
PSP Research LLC manages $141.3M in 13F-reported U.S. long-equity assets across 79 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are SGOV (49.86%), XBI (25.75%), SERA (3.44%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 21 new positions, exited 27, added to 2, and trimmed 47.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$141.3M
Long-equity book
79
Distinct positions
2026-03-31
Filed 2026-04-17
+21 / −27 / ↑2 / ↓47
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- TYRA BIOSCIENCES INC$38.3K +6.7%
- KYMERA THERAPEUTICS INC$30.8K +6.2%
Top Trims
- EYEPOINT INC-$410.6K -76.1%
- OCULAR THERAPEUTIX INC-$393.2K -75.6%
- AMYLYX PHARMACEUTICALS INC-$383.6K -71.8%
- OLEMA PHARMACEUTICALS INC-$327.5K -68.7%
- ALKERMES PLC-$327.3K -60.7%
New Positions
- SPDR SERIES TRUST$36.4M
- SERA PROGNOSTICS INC$4.9M
- DEFINIUM THERAPEUTICS INC$657.7K
- DISC MEDICINE INC$511.5K
- AGIOS PHARMACEUTICALS INC$507.4K
Exited Positions
- TRAVERE THERAPEUTICS INC$583.5K
- JAZZ PHARMACEUTICALS PLC$553.9K
- CG ONCOLOGY INC$551.9K
- BELITE BIO INC$550.7K
- APELLIS PHARMACEUTICALS INC$549.3K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ISHARES TR | SGOV | 46436E718 | $70.5M | 49.86% | 700,000 | SH |
| 2 | SPDR SERIES TRUST | XBI | 78464A870 | $36.4M | 25.75% | 284,900 | SH |
| 3 | SERA PROGNOSTICS INC | SERA | 81749D107 | $4.9M | 3.44% | 2,396,685 | SH |
| 4 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $657.7K | 0.47% | 34,800 | SH |
| 5 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $612.8K | 0.43% | 16,000 | SH |
| 6 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $571.8K | 0.40% | 2,500 | SH |
| 7 | PHARVARIS N V | PHVS | N69605108 | $565.0K | 0.40% | 20,000 | SH |
| 8 | CYTOKINETICS INC | CYTK | 23282W605 | $547.1K | 0.39% | 8,300 | SH |
| 9 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $527.7K | 0.37% | 11,000 | SH |
| 10 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $524.7K | 0.37% | 6,300 | SH |
| 11 | HALOZYME THERAPEUTICS INC | HALO | 40637H109 | $518.7K | 0.37% | 8,026 | SH |
| 12 | EXELIXIS INC | EXEL | 30161Q104 | $512.5K | 0.36% | 11,948 | SH |
| 13 | DISC MEDICINE INC | IRON | 254604101 | $511.5K | 0.36% | 8,000 | SH |
| 14 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $510.6K | 0.36% | 6,800 | SH |
| 15 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $507.4K | 0.36% | 15,000 | SH |
| 16 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $506.9K | 0.36% | 3,848 | SH |
| 17 | INCYTE CORP | INCY | 45337C102 | $498.8K | 0.35% | 5,300 | SH |
| 18 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $491.1K | 0.35% | 7,000 | SH |
| 19 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $488.1K | 0.35% | 15,000 | SH |
| 20 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $484.7K | 0.34% | 1,465 | SH |
| 21 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $483.3K | 0.34% | 1,500 | SH |
| 22 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $480.9K | 0.34% | 2,845 | SH |
| 23 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $480.1K | 0.34% | 15,000 | SH |
| 24 | ARDELYX INC | ARDX | 039697107 | $479.2K | 0.34% | 80,000 | SH |
| 25 | IMMUNOVANT INC | IMVT | 45258J102 | $476.9K | 0.34% | 19,200 | SH |
| 26 | ARGENX SE | ARGX | 04016X101 | $468.1K | 0.33% | 641 | SH |
| 27 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $467.2K | 0.33% | 20,000 | SH |
| 28 | INHIBRX BIOSCIENCES INC | INBX | 45720N103 | $465.7K | 0.33% | 6,927 | SH |
| 29 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $464.1K | 0.33% | 19,700 | SH |
| 30 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $463.0K | 0.33% | 22,100 | SH |
| 31 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $461.9K | 0.33% | 5,000 | SH |
| 32 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $461.9K | 0.33% | 12,000 | SH |
| 33 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $460.6K | 0.33% | 28,000 | SH |
| 34 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $456.5K | 0.32% | 15,141 | SH |
| 35 | CRISPR THERAPEUTICS AG | CRSP | H17182108 | $451.9K | 0.32% | 9,500 | SH |
| 36 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $445.6K | 0.32% | 6,000 | SH |
| 37 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $444.9K | 0.31% | 28,700 | SH |
| 38 | AURINIA PHARMACEUTICALS INC | AUPH | 05156V102 | $444.6K | 0.31% | 30,000 | SH |
| 39 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $440.0K | 0.31% | 19,766 | SH |
| 40 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $438.1K | 0.31% | 14,000 | SH |
| 41 | IMMUNOME INC | IMNM | 45257U108 | $437.4K | 0.31% | 20,000 | SH |
| 42 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $433.4K | 0.31% | 9,000 | SH |
| 43 | TG THERAPEUTICS INC | TGTX | 88322Q108 | $431.9K | 0.31% | 13,000 | SH |
| 44 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $419.6K | 0.30% | 5,000 | SH |
| 45 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $412.4K | 0.29% | 13,000 | SH |
| 46 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $408.8K | 0.29% | 6,000 | SH |
| 47 | VERA THERAPEUTICS INC | VERA | 92337R101 | $402.3K | 0.28% | 10,000 | SH |
| 48 | HARMONY BIOSCIENCES HLDGS IN | HRMY | 413197104 | $400.1K | 0.28% | 14,283 | SH |
| 49 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $399.5K | 0.28% | 11,000 | SH |
| 50 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $392.6K | 0.28% | 71,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-04-17 | $141.3M | 79 | 0001951757-26-000630 |
| 2025-12-31 | 2026-02-06 | $114.4M | 85 | 0001951757-26-000380 |